Table 1.
Characteristics of patients with advanced hepatocellular carcinoma
| All | Sorafenib | Lenvatinib | P‐value | |
|---|---|---|---|---|
| N | 513 | 309 | 204 | |
| Age (years) | 70.0 ± 10.0 | 69.0 ± 10.0 | 71.9 ± 9.6 | 0.001 |
| Sex (male/female) | 426/87 | 261/48 | 165/39 | NS |
| BMI (kg/m2) | 23.3 ± 4.5 | 23.4 ± 5.3 | 23.5 ± 3.7 | NS |
| Etiology (viral/non‐viral) | 312/201 | 207/102 | 106/98 | <0.001 |
| Complication: hypertension | 282 (55%) | 161 (52%) | 121 (59%) | NS |
| Complication: diabetes | 154 (30%) | 88 (28%) | 66 (32%) | NS |
| Pretreatment (TACE/OPE/RFA) | 393/202/162 | 242/134/99 | 151/68/63 | NS |
| PLT (×103/mm4) | 14.7 ± 7.7 | 14.1 ± 7.2 | 15.7 ± 8.4 | 0.025 |
| AST (IU/L) | 51.1 ± 39.2 | 52.7 ± 34.6 | 48.6 ± 45.5 | NS |
| ALT (IU/L) | 36.1 ± 26.9 | 37.9 ± 26.3 | 33.5 ± 27.6 | NS |
| Total bilirubin (mg/dL) | 0.93 ± 0.53 | 0.94 ± 0.57 | 0.91 ± 0.47 | NS |
| Albumin (g/dL) | 3.61 ± 0.54 | 3.63 ± 0.54 | 3.58 ± 0.53 | NS |
| Prothrombin time (INR) | 1.09 ± 0.14 | 1.09 ± 0.13 | 1.09 ± 0.15 | NS |
| AFP (ng/mL) (>400) | 180 (35%) | 117 (38%) | 63 (31%) | NS |
| AFP (ng/mL) (median) | 64.0 | 133.7 | 28.1 | NS |
| DCP (mAU/mL) (>400) | 262 (51%) | 170 (55%) | 92 (45%) | NS |
| DCP (mAU/mL) (median) | 421.0 | 608.0 | 246.0 | NS |
| APRI | 1.12 ± 1.03 | 1.20 ± 1.04 | 1.00 ± 0.99 | NS |
| FIB‐4 index | 5.26 ± 4.43 | 5.25 ± 3.68 | 5.29 ± 5.42 | NS |
| ECOG PS (0/1/2) | 312/104/17 | 200/45/4 | 122/59/13 | NS |
| Child–Pugh grade (A/B) | 399/114 | 253/56 | 146/58 | NS |
| Child–Pugh score | 6.04 ± 1.23 | 6.01 ± 1.20 | 6.07 ± 1.27 | NS |
| ALBI grade (1/2/3) | 166/320/27 | 107/187/15 | 59/133/12 | NS |
| ALBI score | −1.73 ± 0.55 | −1.70 ± 0.55 | −1.76 ± 0.54 | NS |
| TNM stage (2/3/4) | 67/145/265 | 20/78/188 | 47/67/77 | <0.01 |
| Vessel invasion | 107 (21%) | 62 (20%) | 45 (22%) | NS |
| Extrahepatic metastasis | 233 (45%) | 160 (52%) | 73 (35%) | <0.001 |
| Within Up‐to‐7 criteria | 231 (45%) | 155 (50%) | 75 (37%) | 0.007 |
Values are n, n (%), or mean ± SD, unless otherwise specified.
AFP, alpha‐fetoprotein; ALBI, albumin–bilirubin; ALT, alanine aminotransferase; APRI, AST‐to‐platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; DCP, des‐gamma‐carboxy pro‐ thrombin; ECOG PS, Eastern Cooperative Oncology Group performance status; FIB‐4, fibrosis‐4; INR, international normalized ratio; NS, not significant; OPE, operation; PLT, platelet; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization.